|1.||Tugwell, P: 1 article (01/2000)|
|2.||Saenz, A: 1 article (01/2000)|
|3.||Welch, V: 1 article (01/2000)|
|4.||Shea, B: 1 article (01/2000)|
|5.||Wells, G: 1 article (01/2000)|
|6.||Ausejo, M: 1 article (01/2000)|
07/01/1995 - "The degree of joint swelling, the tender joint score and the visual analogue score for pain significantly improved in both groups, but there was no difference in any of these parameters between the groups except for a significant difference in the visual analogue score for less pain at the first week in the azapropazone group (t = 2.23; p < 0.05). "
12/01/1995 - "At the subjective level, analgesic effects of azapropazone were observed in the ratings of tonic pain. "
12/01/1995 - "3. Azapropazone reduced the pain-related CSSERP-amplitudes at frontal and parietal recording positions. "
12/01/1995 - "1. The dose-related effects of azapropazone on (i) event-related and spontaneous EEG-activity and (ii) the subjects' pain ratings were investigated using an experimental human pain model based on both chemo-somatosensory event-related potentials (CSSERP) and subjects' pain ratings. "
12/01/1995 - "Effects of azapropazone on pain-related brain activity in human subjects."
07/01/1995 - "Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study."
07/01/1995 - "We conclude that azapropazone is not effective in controlling the arthritis of Behçet's syndrome."
07/01/1995 - "Sixty-three consecutive Behçet's syndrome patients with an acute arthritis of up to 10 days duration were treated either with azapropazone (APZ) 300 mg t.i.d. "
01/01/1984 - "Azapropazone in arthritis: a long-term treatment."
01/01/2000 - "The main results were the lack of efficacy of some of the classic treatments for Behcet's syndrome, including colchicine, cyclophosphamide and steroids for eye involvement, azapropazone and colchicine for arthritis and acyclovir, colchicine and topical interpheron for aphthas. "
06/01/1990 - "Evaluation of the effect of azapropazone on neutrophil migration in regional myocardial ischaemia/reperfusion injury in rabbits."
02/01/1991 - "The purpose of the present study is to determine the myocardial cytoprotective efficacy of azapropazone (AZA) on regional myocardial function in anesthetized swine model of regional myocardial ischemia/reperfusion injury. "
02/01/1991 - "Myocardial cytoprotective efficacy of azapropazone in a swine model of regional myocardial ischemia/reperfusion injury."
03/15/1986 - "Taken together, the data suggest that the efficacy of azapropazone in gouty arthritis may be partly due to its ability to inhibit key neutrophil functional responses in vivo."
01/01/1983 - "Eight patients with acute gouty arthritis were treated with high dose oral azapropazone 600 mg qds in an open study in order to evaluate its therapeutic potential in acute gout. "
10/01/1989 - "Myocardial cytoprotective efficacy of azapropazone in a canine heart model of regional ischemia and reperfusion."
10/01/1989 - "The present study assessed the efficacy of azapropazone (AZA) in pentobarbital-anesthetized dogs subjected to 120 min of regional ischemia [left anterior descending coronary artery (LAD) ligation] followed by 5 h of reperfusion. "
07/01/1991 - "To evaluate continued intestinal ischemia in the ongoing BT associated with sepsis after injury, rats were randomized to (1) 30% burn injury with Pseudomonas wound infection (BI), (2) BI + fluid resuscitation (BI + Fluid), (3) BI after allopurinol pretreatment to inhibit xanthine oxidase (BI + Allo), or (4) BI after azapropazone pretreatment to inhibit neutrophil degranulation (BI + Aza). "
|9.||Aspirin (Acetylsalicylic Acid)